Phase 2b Trial of Prasinezumab in Patients With Early Parkinson’s Expected by 2021

[Farooqji]

Note:. Prior apologies if someone has already posted it. I am posting this as this is one of the main pipeline item in the ongoing PD trials. Failure or success of future therapies will greatly depend upon the results of this trial.

Roche, in partnership with Prothena, will launch a Phase 2b clinical trial to evaluate the effectiveness of prasinezumab (PRX002/RG7935) — an antibody against the alpha-synuclein protein — in people with early stage Parkinson’s disease, including those on stable levodopa treatment.

The decision was based on positive data from a previous Phase 2 trial, PASADENA (NCT03100149), which, despite failing to meet its main goal of demonstrating prasinezumab can slow the progression of both motor and non-motor symptoms, showed the therapy significantly reduced motor function decline and improved disease biomarkers.

parkinsonsnewstoday.com/202...

[redhawk1]

Have now finished my third infusion in the phase 2b Pasadena study. Initially in phase 2 study for two years with a respite of one year between phase 2 and phase 2b.

As reported preciously my progression has been “slow” but can not decisively attribute it to the Prothena medication. So far no negative reactions to the drug. Cohorts can now enter the trial even though on typical Parkinson’s medications.

Supposedly one of the positive things seen was a slight possible increase in blood flow after being on the drug for seven or so months. Trial expected to run 5 years.

[Farooqji in reply to redhawk1]

Did you know which group were you included? Control (taking placebo) or experimental?

[redhawk1 in reply to Farooqji]

For the first year I may have been on the placebo or the experimental medication . . . have never been privy to that info. For the second year of phase 2 all cohorts were on the medication.

[Farooqji in reply to redhawk1]

Ok thanks. Best of luck